CD8A and neoplasm: The most clinically advanced, pre-treatment biomarkers of ICT responses include CD8+ T cell tumor infiltration (13, 14), intra-tumoral PD-L1 expression (13, 15), tumor mutation burden and neo-antigen burden (16, 17).